Targovax ASA, of Oslo, Norway, presented results from an observational clinical study with RAS peptide vaccine TG-01 in nonresectable pancreatic cancer patients, showing that 14 of 25 patients (56 percent) had a positive delayed type hypersensitivity (DTH) skin reaction test by week 10.